PI3Kα-IN-27
PI3Kα-IN-27 (Compound 50b) is an orally active PI3K-α inhibitor, with an IC50 of 40 nM. PI3Kα-IN-27 effectively inhibits PAK3, p110α, phospho-mTOR and phospho-ERK1/2. PI3Kα-IN-27 induces early Apoptosis. PI3Kα-IN-27 shows anticancer activity against pancreatic cancer, lung cancer, breast cancer[1].
Product Specifications
CAS Number
2098649-83-1
UNSPSC
12352005
Target
Apoptosis; mTOR; PAK; PERK; PI3K
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; PI3K/Akt/mTOR
Field of Research
Cancer
Smiles
O=C(NC1CCN(C2=NC(N3CCOCC3)=C4C(C=CS4)=N2)CC1)NC5=CC=C(CC)C=C5
Molecular Formula
C24H30N6O2S
Molecular Weight
466.60
References & Citations
[1]Mohammed S, et al. Discovery of 2- (4-Ureido-piperidin-1-yl) -4-morpholinothieno [3,2-D] Pyrimidines as Orally Bioavailable Phosphoinositide-3-Kinase Inhibitors with In Vitro and In Vivo Antitumor Efficacy in Triple-Negative Breast Cancer. J Med Chem. 2025 Oct 23;68 (20) :21282-21317.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PAK3; PI3Kα
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-D462763-250MG 250 mg
6-(Dibutylamino)-1,3,5-triazine-2,4-dithiol
Sign In for Pricing
View Details